These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 20014904)

  • 1. Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.
    Giuliano C; Haase KK; Hall R
    Expert Rev Anti Infect Ther; 2010 Jan; 8(1):95-106. PubMed ID: 20014904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of initial vancomycin pharmacokinetic/pharmacodynamic parameters on the clinical and microbiological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children.
    Yoo R; So H; Seo E; Kim M; Lee J
    PLoS One; 2021; 16(4):e0247714. PubMed ID: 33793589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation.
    Frymoyer A; Hersh AL; Coralic Z; Benet LZ; Joseph Guglielmo B
    Clin Ther; 2010 Mar; 32(3):534-42. PubMed ID: 20399990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/Pharmacodynamic Target Attainment of Vancomycin, at Three Reported Infusion Modes, for Methicillin-Resistant
    Song X; Han M
    Front Cell Infect Microbiol; 2022; 12():874401. PubMed ID: 35873144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.
    Frymoyer A; Hersh AL; Benet LZ; Guglielmo BJ
    Pediatr Infect Dis J; 2009 May; 28(5):398-402. PubMed ID: 19295465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia.
    Harigaya Y; Bulitta JB; Forrest A; Sakoulas G; Lesse AJ; Mylotte JM; Tsuji BT
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3894-901. PubMed ID: 19596879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
    Arun A; Swamy S; Jacob K; Sharma R; Kohlhoff SA; Hammerschlag MR
    Minerva Pediatr; 2018 Jun; 70(3):207-211. PubMed ID: 28006894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant].
    Lepe JA; Gil-Navarro MV; Santos-Rubio MD; Bautista J; Aznar J
    Rev Esp Quimioter; 2010 Mar; 23(1):43-7. PubMed ID: 20232023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia.
    Yeh YC; Yeh KM; Lin TY; Chiu SK; Yang YS; Wang YC; Lin JC
    J Microbiol Immunol Infect; 2012 Jun; 45(3):214-20. PubMed ID: 22571999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
    Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
    J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Best alternative to vancomycin for serious methicillin-resistant Staphylococcus aureus infections: let's just say it.
    Bush LM
    Clin Infect Dis; 2011 Nov; 53(9):965-6. PubMed ID: 21880584
    [No Abstract]   [Full Text] [Related]  

  • 14. Sequence Type 5 (ST5) as a Possible Predictor of Bacterial Persistence in Adult Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia Treated with Vancomycin.
    Fan YX; Chen MT; Li NY; Liu XF; Yang MJ; Chen YC; Liang XY; Wu JF; Guo BN; Song SC; Zhu YQ; Zhang FY; Hang JQ; Wu SB; Shen B; Li HY; Wang Q; Luo XM; Chen QG; Zhang HF; Wang RL; Shen LH; Fu FM; Song XL; Zhang J
    Microbiol Spectr; 2022 Oct; 10(5):e0134822. PubMed ID: 36094217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
    Kullar R; Davis SL; Levine DP; Rybak MJ
    Clin Infect Dis; 2011 Apr; 52(8):975-81. PubMed ID: 21460309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.
    Nicasio AM; Bulitta JB; Lodise TP; D'Hondt RE; Kulawy R; Louie A; Drusano GL
    Antimicrob Agents Chemother; 2012 Feb; 56(2):682-6. PubMed ID: 22083484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials.
    Hos NJ; Jazmati N; Stefanik D; Hellmich M; AlSael H; Kern WV; Rieg S; Wisplinghoff H; Seifert H; Kaasch AJ
    J Infect; 2017 Mar; 74(3):248-259. PubMed ID: 28017826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus.
    Patel N; Lubanski P; Ferro S; Bonafede M; Harrington S; Evans A; Stellrecht K; Lodise TP
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5141-4. PubMed ID: 19805558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children?
    Jimenez-Truque N; Thomsen I; Saye E; Creech CB
    Pediatr Infect Dis J; 2010 Apr; 29(4):368-70. PubMed ID: 19935448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growing Resistance to Vancomycin among Methicillin Resistant Staphylococcus Aureus Isolates from Different Clinical Samples.
    Pahadi PC; Shrestha UT; Adhikari N; Shah PK; Amatya R
    JNMA J Nepal Med Assoc; 2014; 52(196):977-81. PubMed ID: 26982895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.